Into the twilight zone – should ER-low breast cancer be treated as triple negative breast cancer?
Main Authors: | Helena Jernström, Lisa Rydén |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-05-01
|
Series: | The Lancet Regional Health. Europe |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776224000620 |
Similar Items
-
Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
by: Paolo Peterlongo, et al.
Published: (2021-09-01) -
ERβ in Triple-Negative Breast Cancer: Emerging Concepts and Therapeutic Possibilities
by: Alessandra Monaco, et al.
Published: (2021-09-01) -
Triple negative breast cancer: Pitfalls and progress
by: Paola Zagami, et al.
Published: (2022-08-01) -
Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
by: Yingnan Si, et al.
Published: (2021-07-01) -
In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer
by: Najat Bouchmaa, et al.
Published: (2023-01-01)